Zobrazeno 1 - 10
of 105
pro vyhledávání: '"Howard H. Feldman"'
Autor:
Douglas Galasko, Martin R. Farlow, Brendan P. Lucey, Lawrence S. Honig, Donald Elbert, Randall Bateman, Jeremiah Momper, Ronald G. Thomas, Robert A. Rissman, Judy Pa, Vahan Aslanyan, Archana Balasubramanian, Tim West, Maria Maccecchini, Howard H. Feldman
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-15 (2024)
Abstract Background Amyloid beta protein (Aβ) is a treatment target in Alzheimer’s Disease (AD). Lowering production of its parent protein, APP, has benefits in preclinical models. Posiphen, an orally administered small molecule, binds to an iron-
Externí odkaz:
https://doaj.org/article/e42d62be4d5d45feab248f4b5d8078a5
Autor:
Khushbu J. Patel, David Yang, John R. Best, Colleen Chambers, Philip E. Lee, Alexandre Henri‐Bhargava, Clark R. Funnell, Dean J. Foti, Jacqueline A. Pettersen, Howard H. Feldman, Haakon B. Nygaard, Ging‐Yuek R. Hsiung, Mari L. DeMarco
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 2, Pp n/a-n/a (2024)
Abstract INTRODUCTION In the Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia (IMPACT‐AD BC) study, we aimed to understand how Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker testing—used in medical car
Externí odkaz:
https://doaj.org/article/0b3ef9451f9848b3a2c74e5b3e057d1f
Autor:
Khushbu J. Patel, David Yang, Howard H. Feldman, Ging‐Yuek R. Hsiung, Haakon B. Nygaard, John R. Best, Emily Dwosh, Julie M. Robillard, Mari L. DeMarco
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 2, Pp n/a-n/a (2024)
Abstract INTRODUCTION We described patients’ and care partners’ experiences with Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker testing and result disclosure in routine care. METHODS IMPACT‐AD BC is an observational study of clini
Externí odkaz:
https://doaj.org/article/9621bc82cc234204941cd46af4cac87f
Autor:
Howard H. Feldman, José A. Luchsinger, Gabriel C. Léger, Curtis Taylor, Diane M. Jacobs, David P. Salmon, Steven D. Edland, Karen Messer, Carolyn Revta, Sarah A. Flowers, Kerry S. Jones, Albert Koulman, Kevin E. Yarasheski, Philip B. Verghese, Venky Venkatesh, Henrik Zetterberg, January Durant, Jody-Lynn Lupo, Gary E. Gibson
Publikováno v:
PLoS ONE, Vol 19, Iss 5 (2024)
Externí odkaz:
https://doaj.org/article/f3a36adabb974ff7a96f2ebf7f1eeb94
Autor:
Sara Moukarzel, Zvinka Z. Zlatar, Sheri J. Hartman, Derek Lomas, Howard H. Feldman, Sarah J. Banks, HALT‐AD Study Group
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 10, Iss 1, Pp n/a-n/a (2024)
Abstract INTRODUCTION With Alzheimer's disease and related dementias (ADRD) representing an enormous public health challenge, there is a need to support individuals in learning about and addressing their modifiable risk factors (e.g., diet, sleep, an
Externí odkaz:
https://doaj.org/article/dd5ab4174ccc463bb76476c25578ba85
Autor:
Nicholas C. Cullen, Petr Novak, Duygu Tosun, Branislav Kovacech, Jozef Hanes, Eva Kontsekova, Michal Fresser, Stefan Ropele, Howard H. Feldman, Reinhold Schmidt, Bengt Winblad, Norbert Zilka
Publikováno v:
EBioMedicine, Vol 99, Iss , Pp 104923- (2024)
Summary: Background: Tau pathology correlates with and predicts clinical decline in Alzheimer’s disease. Approved tau-targeted therapies are not available. Methods: ADAMANT, a 24-month randomised, placebo-controlled, parallel-group, double-blinded,
Externí odkaz:
https://doaj.org/article/5abb6ea1343b438281cf67da9a9d0413
Autor:
Ben Boyarko, Sonia Podvin, Barry Greenberg, Jeremiah D. Momper, Yadong Huang, William H. Gerwick, Anne G. Bang, Luisa Quinti, Ana Griciuc, Doo Yeon Kim, Rudolph E. Tanzi, Howard H. Feldman, Vivian Hook
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Therapeutics discovery and development for Alzheimer’s disease (AD) has been an area of intense research to alleviate memory loss and the underlying pathogenic processes. Recent drug discovery approaches have utilized in silico computational strate
Externí odkaz:
https://doaj.org/article/d3f3f5cf111246e3bec8557366792dd9
Autor:
Manuel Montero-Odasso, G Y Zou, Nellie Kamkar, Howard H. Feldman, Sylvie Belleville, Howard Chertkow, Haakon B Nygaard, Surim Son, Mark Speechley
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-5 (2022)
Abstract Background Multidomain trials to prevent dementia by simultaneously targeting multiple risk factors with non-pharmacological lifestyle interventions show promise. Designing trials to evaluate the efficacy of individual interventions and thei
Externí odkaz:
https://doaj.org/article/17a5e15e47e6440bbcf87ad6e67d5092
Autor:
Lon S. Schneider, Yuqi Qiu, Ronald G. Thomas, Carol Evans, Diane M. Jacobs, Shelia Jin, Jeffrey A. Kaye, Andrea Z. LaCroix, Karen Messer, David P. Salmon, Mary Sano, Kimberly Schafer, Howard H. Feldman
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-13 (2021)
Abstract Background The COVID-19 pandemic disrupted Alzheimer disease randomized clinical trials (RCTs), forcing investigators to make changes in the conduct of such trials while endeavoring to maintain their validity. Changing ongoing RCTs carries r
Externí odkaz:
https://doaj.org/article/f3949063de124d12abb87b3f1b863f03
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Graphical AbstractSummary of the study.
Externí odkaz:
https://doaj.org/article/0c398ee6544545fc9f6bf32dae0026c3